Format

Send to

Choose Destination
J Breast Cancer. 2018 Mar;21(1):87-90. doi: 10.4048/jbc.2018.21.1.87. Epub 2018 Mar 23.

Identification of the Thioredoxin-Like 2 Autoantibody as a Specific Biomarker for Triple-Negative Breast Cancer.

Chung JM1,2,3, Jung Y4, Kim YP5, Song J5, Kim S1,2,3, Kim JY4, Kwon M1,2,3, Yoon JH1,2,3, Kim MD5, Lee JK1, Chung DY5, Lee SY1,2, Kang J5, Kang HC1,2,3.

Author information

1
Genomic Instability Research Center, Ajou University School of Medicine, Suwon, Korea.
2
Department of Physiology, Ajou University School of Medicine, Suwon, Korea.
3
Department of Biomedical Sciences, Ajou University School of Medicine, Suwon, Korea.
4
Department of Surgery, Ajou University School of Medicine, Suwon, Korea.
5
Department of Bio-Engineering, Life Science RD Center, Sinil Pharmaceutical Co., Seongnam, Korea.

Abstract

Triple-negative breast cancer (TNBC) has a higher risk of death within 5 years of being diagnosed than the other forms of breast cancer. It is the second leading cause of death due to cancer among women. Currently, however, no diagnostic blood-based biomarker exists to identify the early stages of TNBC. To address this point, we utilized a human protein microarray system to identify serum autoantibodies that showed different expression patterns between TNBC and normal serum samples, and identified five autoantibodies showing TNBC-specific expression. Among them, we selected the thioredoxin-like 2 (TXNL2) autoantibody and evaluated its diagnostic relevance by dot blot analysis with the recombinant TXNL2 protein. We demonstrated that the TXNL2 autoantibody showed 2- to 6-fold higher expression in TNBC samples than in normal samples suggesting that serum TXNL2 autoantibodies are potential biomarkers for TNBC.

KEYWORDS:

Autoantibodies; Biomarkers; Breast neoplasms; Protein array analysis

Conflict of interest statement

CONFLICT OF INTEREST: The authors declare that they have no competing interests.

Supplemental Content

Full text links

Icon for Korean Breast Cancer Society Icon for PubMed Central
Loading ...
Support Center